Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | TNKS | O95271 | 5/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.34 |
| ▸ | PARP1 | P09874 | 4/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.32 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.32 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15288923 | 0.77 | TNKS (0.60) | FLT3SYKAURKBKDM5BBRD4 | |
| SCHEMBL15294716 | 0.76 | BRD4 (0.42) | FLT3SYKKDM5BBRD4CREBBP | |
| SCHEMBL15287295 | 0.73 | TNKS (0.57) | FLT3SYKKDM5BBRD4CREBBP | |
| SCHEMBL15287075 | 0.72 | TNKS (0.46) | FLT3SYKKDM5BBRD4CREBBP | |
| SCHEMBL16427534 | 0.71 | KDM4E (0.49) | — | |
| SCHEMBL25609010 | 0.69 | KDM4E (0.33) | — | |
| SCHEMBL16428453 | 0.69 | PDE3B (0.42) | KDM5BTNKS | |
| SCHEMBL17102322 | 0.67 | SYK (0.48) | FLT3SYKAURKBKDM5BBRD4 | |
| SCHEMBL20074321 | 0.62 | KDM5B (0.38) | FLT3SYKAURKBKDM5BBRD4 | |
| SCHEMBL15527419 | 0.62 | SPR (0.41) | BRD4CREBBPEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-3027601-A1 | SYK INHIBITORS | Gilead Sciences, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | FLT3 9/4885SYK 1/4885AURKB 439/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | FLT3 9/4885SYK 1/4885AURKB 454/4885 |
| US-10005774-B2 | Syk inhibitors | SYK, BTK, LYN | FLT3 9/4885SYK 1/4885AURKB 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.